Mezigdomide after Abecma for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called mezigdomide (CC-92480) for people with multiple myeloma who have already received the CAR T-cell therapy Abecma. The goal is to see if mezigdomide can help keep the cancer under control after Abecma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received the CAR T-cell therapy called Abecma (idecabtagene vicleucel) between 30 and 90 days ago.
- Your multiple myeloma did not get worse after Abecma (at least stable disease).
- You have tried at least 4 different treatments before, including a drug that boosts the immune system, a drug that blocks the proteasome, and a drug that targets CD38 (like daratumumab).
- Your blood counts (neutrophils and platelets) are high enough, and your liver and kidney function are within safe limits.
- You are not currently taking strong immunosuppressants or certain medications that could interfere with the study drug.
- You are not pregnant, and if you could become pregnant, you agree to follow the pregnancy prevention plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
This trial tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to treatment, specifically after they have received a therapy named idecabtagene vicleucel (Abecma). It aims to see if elranatamab can help control the disease.
This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.